The Role of Steroid Sulfatase as a Prognostic Factor in Patients with Endometrial Cancer

키워드

참고문헌 (33)

1. Sherman ME, "Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis", J Cell Biochem Suppl, 23, pp.160~164 (1995)
2. Sherman ME, "Theories of endometrial carcinogenesis: a multidisciplinary approach", Mod Pathol, 13, pp.295~308 (2000)
3. Thomas DB, "Do hormones cause breast cancer?", Cancer, 53(3Suppl), pp.595~604 (1984)
4. Kelsey JL, "A case-control study of cancer of the endometrium", Am J Epidemiol, 116, pp.333~342 (1982)
5. Ryan KJ, "Editorial: Cancer risk and estrogen use in the menopause", N Engl J Med, 293, pp.1199~1200 (1975)
6. Reed MJ, "Steroid sulfatase: molecular biology, regulation, and inhibition", Endocr Rev, 26, pp.171~202 (2005)
7. Woo LW, "Development of steroid sulfatase inhibitors", Mol Cell Endocrinol, 340, pp.175~185 (2011)
8. Geisler J, "Steroid sulfatase inhibitors:promising new tools for breast cancer therapy?", J Steroid Biochem Mol Biol, 125, pp.39~45 (2011)
9. Masamura S, "Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells", J Clin Endocrinol Metab, 80, pp.2918~2925 (1995)
10. Sasano H, "Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1in human breast carcinoma", J Clin Endocrinol Metab, 81, pp.4042~4046 (1996)
11. Utsunomiya H, "The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma", J Clin Endocrinol Metab, 86, pp.3436~3443 (2001)
12. Tokunaga K, "Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers", Cancer Res, 47, pp.5616~5619 (1987)
13. Utsunomiya H, "Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma", Clin Cancer Res, 10, pp.5850~5856 (2004)
14. Purohit A, "In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE", Cancer Res, 60, pp.3394~3396 (2000)
15. Foster PA, "In vivo effcacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy", Clin Cancer Res, 12, pp.5543~5549 (2006)
16. Foster PA, "Effcacy of three potent steroid sulfatase inhibitors: preclinical investigations for their use in the treatment of hormonedependent breast cancer", Breast Cancer Res Treat, 111, pp.129~138 (2008)
17. Stanway SJ, "Phase I study of STX 64 (667 Coumate) in breast cancer patients:the first study of a steroid sulfatase inhibitor", Clin Cancer Res, 12, pp.1585~1592 (2006)
18. Foster PA, "The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer", Endocrinology, 149, pp.4035~4042 (2008)
19. Selcer KW, "Immunohistochemical analysis of steroid sulfatase in human tissues", J Steroid Biochem Mol Biol, 105, pp.115~123 (2007)
20. Greggi S, "Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study", Int J Gynecol Cancer, 21, pp.661~667 (2011)
21. Ayeni TA, "Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas", Gynecol Oncol, 129, pp.478~485 (2013)
22. Cohen I, "Endometrial pathologies associated with postmenopausal tamoxifen treatment", Gynecol Oncol, 94, pp.256~266 (2004)
23. Neven P, "Controversies regarding tamoxifen and uterine carcinoma", Curr Opin Obstet Gynecol, 10, pp.9~14 (1998)
24. Slomovitz BM, "Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?", Obstet Gynecol, 104, pp.255~260 (2004)
25. DeMichele A, "Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study", J Clin Oncol, 26, pp.4151~4159 (2008)
26. Berstein L, "Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects", Eur J Obstet Gynecol Reprod Biol, 105, pp.161~165 (2002)
27. Barker LC, "Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma", Curr Med Res Opin, 25, pp.1105~1109 (2009)
28. Ma BB, "The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group", Int J Gynecol Cancer, 14, pp.650~658 (2004)
29. Couse JF, "Receptor null mice reveal contrasting roles for estrogen receptor alpha and beta in reproductive tissues", J Steroid Biochem Mol Biol, 74, pp.287~296 (2000)
30. Kuiper GG, "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta", Endocrinology, 138, pp.863~870 (1997)
31. Bryant W, "The estrogen receptor (ER)alpha variant Delta5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells", Endocrinology, 146, pp.751~759 (2005)
32. Lin SL, "A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells", Reprod Biol Endocrinol, 7, pp.102~ (2009)
33. Ogawa S, "Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human", Nucleic Acids Res, 26, pp.3505~3512 (1998)

관련 논문AI추천